Center-Authored Papers

Filters: Author is Thompson, John A  [Clear All Filters]
2008
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM et al..  2008.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(16):5260-9. Abstract
Tykodi SS, Thompson JA.  2008.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.. Expert opinion on biological therapy. 8(12):1947-53. Abstract
Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C.  2008.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.. The New England journal of medicine. 358(25):2698-703. Abstract
2009
Wallen H, Thompson JA, Reilly ZJ, Rodmyre RM, Cao J, Yee C.  2009.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.. PloS one. 4(3):e4749. Abstract
Bhatia S, Tykodi SS, Thompson JA.  2009.  Treatment of metastatic melanoma: an overview.. Oncology (Williston Park, N.Y.). 23(6):488-96. Abstract
2010
Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB.  2010.  Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.. Digestive diseases and sciences. 55(5):1396-405. Abstract
2011
Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR et al..  2011.  Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(24):7765-7775. Abstract
Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJA, Dummer R, Davidson N et al..  2011.  Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).. European journal of cancer (Oxford, England : 1990). 47(10):1476-83. Abstract
Tykodi SS, Sandmaier BM, Warren EH, Thompson JA.  2011.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.. Expert opinion on biological therapy. 11(6):763-73. Abstract
2012
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D et al..  2012.  Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(12):1371-7. Abstract
Thompson JA.  2012.  Ten years of progress in melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(8):932-5.
Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS.  2012.  Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial.. Journal of immunotherapy (Hagerstown, Md. : 1997). 35(1):73-77. Abstract
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC et al..  2012.  Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):366-400.
Bhatia S, Thompson JA.  2012.  Systemic therapy for metastatic melanoma in 2012: dawn of a new era.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):403-12. Abstract
Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J et al..  2012.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.. Proceedings of the National Academy of Sciences of the United States of America. 109(12):4592-7. Abstract
2013
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC et al..  2013.  Melanoma, version 2.2013: featured updates to the NCCN guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(4):395-407. Abstract
Sharma A, Thompson JA, Repaka A, Mehnert JM.  2013.  Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(21):e370-2.
2014
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y et al..  2014.  A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.. Cancer. 120(11):1647-55. Abstract
Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P et al..  2014.  Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.. Journal for immunotherapy of cancer. 2:2. Abstract
Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, Bhrany AD, Hawes SE, Ladra M.  2014.  Fast neutron radiotherapy for primary mucosal melanomas of the head and neck.. Head & neck. 36(8):1162-7. Abstract
Bhatia S, Thompson JA.  2014.  Melanoma: immune checkpoint blockade story gets better.. Lancet.
Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A et al..  2014.  Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.. Cancer immunology research. Abstract
McDermott D, Lebbé C, Hodi SF, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM.  2014.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.. Cancer treatment reviews. Abstract
Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY.  2014.  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.. European journal of cancer (Oxford, England : 1990). Abstract